Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.64 |
| ▸ | BRAF | P15056 | 10/20 | 0.63 |
| ▸ | KDR | P35968 | 9/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.63 |
| ▸ | RET | P07949 | 3/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.63 |
| ▸ | TTK | P33981 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3841018 | 0.99 | RAF1 (0.63) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL672388 | 0.90 | RAF1 (0.74) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL432444 | 0.88 | RAF1 (0.82) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL29643339 | 0.88 | RAF1 (0.82) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL16965302 | 0.84 | RAF1 (0.63) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL4238109 | 0.81 | RAF1 (0.82) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL4609009 | 0.80 | BRAF (0.82) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL16965298 | 0.78 | BRAF (0.66) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL12333608 | 0.78 | RAF1 (0.82) | RAF1BRAFKDRMAPK14RET | |
| SCHEMBL22627130 | 0.78 | RAF1 (0.85) | RAF1BRAFKDRMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155674-A1 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155674-A1 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER | PDCD1, CD274, PDCD1LG2 | RAF1 18/4885BRAF 9/4885KDR 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.